









市场行情
/
股票
/
nasdaq-imvt
/

Immunovant Inc

IMVT

23.370USD

+0.020+0.09%

收盘 11/10, 16:00（美东）报价延迟15分钟

4.00B总市值

亏损市盈率 TTM



Immunovant Inc

23.370

+0.020+0.09%

概览公司财务分析

概览

公司

财务

分析

关于 Immunovant Inc 公司

Immunovant, Inc. 是一家临床阶段免疫学公司。该公司专注于开发自身免疫性疾病患者的治疗方法。其产品线包括巴托利单抗和 IMVT-1402，这两种都是新型的全人源单克隆抗体，靶向新生儿可结晶片段受体 (FcRn)。巴托利单抗是一种皮下注射剂。据观察，巴托利单抗可降低引起炎症和疾病的免疫球蛋白 G (IgG) 抗体。其候选产品巴托利单抗采用小剂量给药，并使用 27 号针头。该公司正在开发用于治疗重症肌无力 (MG)、甲状腺眼病 (TED)、慢性炎症性脱髓鞘性多发性神经病 (CIDP) 和格雷夫斯病 (GD) 的巴托利单抗。其主要候选产品 IMVT-1402 还被观察到在健康成人中进行的 I 期临床试验中可降低 IgG 抗体水平。 IMVT-1402 是一种抑制 FcRn 的完全人源单克隆抗体。

Immunovant Inc简介



公司代码IMVT

公司名称Immunovant Inc

上市日期May 14, 2019

CEODr. Eric Venker, M.D.

员工数量362

证券类型Ordinary Share

年结日May 14

公司地址320 West 37Th Street

城市NEW YORK

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编10018

电话19175803099

网址https://immunovant.com/

公司代码IMVT

上市日期May 14, 2019

CEODr. Eric Venker, M.D.

Immunovant Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Frank M. Torti, M.D.

Executive Chairman of the Board

615.44K

-6.15%

Ms. Melanie Gloria

Chief Operating Officer

186.14K

+69.28%

Mr. Douglas J. Hughes

Independent Director

119.58K

-3.96%

Dr. Atul Pande, M.D.

Independent Director

95.41K

-14.51%

Mr. Andrew J. (Drew) Fromkin

Director

91.91K

-5.09%

Dr. Jay S. Stout, Ph.D.

Chief Technology Officer

77.09K

-5.06%

Dr. Michael Geffner, M.D.

Chief Medical Officer

41.09K

-8.60%

Mr. Jacob (Jake) Bauer

Independent Director

Mr. Robert G. Susman

Independent Director

Mr. Tiago Girao

Chief Financial Officer

名称

名称/职务

职务

持股

持股变动

Dr. Frank M. Torti, M.D.

Executive Chairman of the Board

615.44K

-6.15%

Ms. Melanie Gloria

Chief Operating Officer

186.14K

+69.28%

Mr. Douglas J. Hughes

Independent Director

119.58K

-3.96%

Dr. Atul Pande, M.D.

Independent Director

95.41K

-14.51%

Mr. Andrew J. (Drew) Fromkin

Director

91.91K

-5.09%

Dr. Jay S. Stout, Ph.D.

Chief Technology Officer

77.09K

-5.06%

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

Roivant Sciences Ltd.

55.45%

Fidelity Management & Research Company LLC

10.51%

Deep Track Capital LP

5.45%

T. Rowe Price Investment Management, Inc.

3.95%

The Vanguard Group, Inc.

3.91%

其他

20.74%

持股股东

占比

Roivant Sciences Ltd.

55.45%

Fidelity Management & Research Company LLC

10.51%

Deep Track Capital LP

5.45%

T. Rowe Price Investment Management, Inc.

3.95%

The Vanguard Group, Inc.

3.91%

其他

20.74%

股东类型

持股股东

占比

Corporation

55.45%

Investment Advisor

26.94%

Hedge Fund

18.10%

Investment Advisor/Hedge Fund

6.09%

Research Firm

2.00%

Individual Investor

1.82%

Private Equity

1.23%

Sovereign Wealth Fund

0.39%

Pension Fund

0.38%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

487

96.71M

55.48%

-16.70M

2025Q2

493

194.27M

113.56%

-2.08M

2025Q1

505

194.81M

114.45%

+16.42M

2024Q4

482

163.29M

104.53%

-8.19M

2024Q3

464

162.18M

111.33%

-1.06M

2024Q2

453

157.67M

108.50%

+1.66M

2024Q1

433

151.47M

104.51%

-605.85K

2023Q4

420

150.13M

103.75%

+991.03K

2023Q3

373

143.75M

105.86%

+4.45M

2023Q2

335

132.11M

101.25%

-11.81M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Roivant Sciences Ltd.

96.65M

55.45%

Apr 21, 2025

Fidelity Management & Research Company LLC

18.33M

10.51%

+2.20M

+13.67%

Jun 30, 2025

Deep Track Capital LP

9.50M

5.45%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

6.88M

3.95%

+984.13K

+16.69%

Jun 30, 2025

The Vanguard Group, Inc.

7.01M

4.02%

+92.23K

+1.33%

Jun 30, 2025

Baker Bros. Advisors LP

5.46M

3.13%

Jun 30, 2025

Armistice Capital LLC

5.20M

2.98%

+700.00K

+15.56%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.11M

2.93%

+362.12K

+7.63%

Jun 30, 2025

Point72 Asset Management, L.P.

3.34M

1.91%

+2.53M

+316.03%

Jun 30, 2025

State Street Investment Management (US)

2.83M

1.62%

-257.02K

-8.33%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

0.73%

SPDR S&P Biotech ETF

0.42%

ProShares Ultra Nasdaq Biotechnology

0.29%

Invesco Nasdaq Biotechnology ETF

0.28%

Direxion Daily S&P Biotech Bull 3X Shares

0.22%

iShares Biotechnology ETF

0.11%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.07%

iShares Russell 2000 Growth ETF

0.07%

Strive Small-Cap ETF

0.05%

BNY Mellon US Small Cap Core Equity ETF

0.05%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.73%

SPDR S&P Biotech ETF

占比0.42%

ProShares Ultra Nasdaq Biotechnology

占比0.29%

Invesco Nasdaq Biotechnology ETF

占比0.28%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.22%

iShares Biotechnology ETF

占比0.11%

JPMorgan BetaBuilders US Small Cap Equity ETF

占比0.07%

iShares Russell 2000 Growth ETF

占比0.07%

Strive Small-Cap ETF

占比0.05%

BNY Mellon US Small Cap Core Equity ETF

占比0.05%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

KeyAI

